We can't find the internet
Attempting to reconnect
18282.2 PFLS-LS
Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues
Résumé
Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues
Textes supplémentaires
Abstract
The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide|Therapy (PRRT).
Participants
Alan Harris
Wirtschaftspartner
SomTheranostics Sàrl Alan Harris Chemin de Beaufort 12 1162 St-Prex VD CH
Melpomeni Fani
Kontaktperson
Melpomeni.Fani@usb.ch
Universitätsspital Basel Melpomeni Fani Petersgraben 4 4031 Basel BS CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2016-03-31
- Date de fin
- 2018-04-30
- Coûts totaux approuvés
- CHF 276336.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T115 Medical technology 100.0%